Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Management of participants with low-level persistent viremia
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborator:
Janssen-Cilag Ltd.
Treatments:
Darunavir HIV Protease Inhibitors Protease Inhibitors Raltegravir Potassium Ritonavir